Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Haruyoshi Tanaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0079-8422; OpenAlex author ID A5062814101. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 5 papers · 2026: 1 paper

Papers 10

  1. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… First author DOI 10.1002/ijc.70801↗
  2. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  3. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03167-2↗
  4. FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (G… Co-author DOI 10.1093/bjs/znaf049↗
  5. Risk Factors for Early Liver Recurrence After Pancreatic Cancer Resection. Co-author DOI 10.1097/mpa.0000000000002441↗
  6. Exploration of Lipid Mediators for Therapeutic Monitoring of Pancreatic Cancer Patients. Co-author DOI 10.21873/anticanres.17520↗
  7. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peri… Co-author DOI 10.1002/ags3.12719↗
  8. Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytolog… Co-author DOI 10.1002/jhbp.1356↗
  9. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  10. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2021.10.008↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tsutomu Fujii · 7 shared papers, 2023–2026 · strength 1.38
  2. Mina Fukasawa · 4 shared papers, 2023–2025 · strength 0.83
  3. Mitsuro Kanda · 3 shared papers, 2025–2026 · strength 0.65
  4. Nobuhiko Nakagawa · 3 shared papers, 2025–2026 · strength 0.64
  5. Nana Kimura · 3 shared papers, 2023–2025 · strength 0.63
  6. Kenichi Hirabayashi · 3 shared papers, 2023–2025 · strength 0.58
  7. Masamichi Hayashi · 2 shared papers, 2025–2026 · strength 0.44
  8. Junpei Yamaguchi · 2 shared papers, 2025–2026 · strength 0.42
  9. Tomoki Ebata · 2 shared papers, 2025–2026 · strength 0.42
  10. Tomohisa Otsu · 2 shared papers, 2025 · strength 0.42
  11. Yasuhiro Kodera · 2 shared papers, 2025 · strength 0.42
  12. Ayaka Itoh · 2 shared papers, 2023–2024 · strength 0.39
  13. Sohei Satoi · 2 shared papers, 2023–2025 · strength 0.32
  14. Yoshifumi Takeyama · 2 shared papers, 2023–2025 · strength 0.32
  15. Jin Peng He · 2 shared papers, 2022–2023 · strength 0.27
  16. Yoshihiro Shirai · 1 shared paper, 2025 · strength 0.25
  17. Katsuhisa Hirano · 1 shared paper, 2025 · strength 0.25
  18. Shinji Naganawa · 1 shared paper, 2026 · strength 0.22
  19. Hiroki Kawashima · 1 shared paper, 2026 · strength 0.22
  20. Yukihiro Yokoyama · 1 shared paper, 2026 · strength 0.22
  21. Hironori Yamada · 1 shared paper, 2026 · strength 0.22
  22. Osamu Maeda · 1 shared paper, 2026 · strength 0.22
  23. Fuminori Sonohara · 1 shared paper, 2025 · strength 0.22
  24. Norifumi Hattori · 1 shared paper, 2025 · strength 0.22
  25. Kuntal Halder · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.